International Stem Cell (ISCO) Stock Overview

A clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. More details

ISCO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 63.7% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap ($1M)

Highly volatile share price over the past 3 months compared to the US market

ISCO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

International Stem Cell Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for International Stem Cell
Historical stock prices
Current Share Price	US$0.13
52 Week High	US$0.27
52 Week Low	US$0.081
Beta	0.12
1 Month Change	-12.31%
3 Month Change	0.85%
1 Year Change	15.32%
3 Year Change	0.77%
5 Year Change	-68.02%
Change since IPO	-99.97%

Recent updates

Shareholder Returns

	ISCO	US Biotechs	US Market
7D	-2.9%	3.3%	3.1%
1Y	15.3%	26.7%	14.6%

Return vs Industry: ISCO underperformed the US Biotechs industry which returned 25.9% over the past year.

Return vs Market: ISCO exceeded the US Market which returned 14.2% over the past year.

Price Volatility

Is ISCO's price volatile compared to industry and market?
ISCO volatility
ISCO Average Weekly Movement	20.6%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.4%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ISCO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ISCO's weekly volatility has decreased from 31% to 21% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2001	32	Andrey Semechkin	www.internationalstemcell.com

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.

International Stem Cell Corporation Fundamentals Summary

How do International Stem Cell's earnings and revenue compare to its market cap?
ISCO fundamental statistics
Market cap	US$1.05m
Earnings (TTM)	-US$59.00k
Revenue (TTM)	US$9.39m

0.1x

P/S Ratio

-17.8x

P/E Ratio

Is ISCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ISCO income statement (TTM)
Revenue	US$9.39m
Cost of Revenue	US$3.96m
Gross Profit	US$5.43m
Other Expenses	US$5.49m
Earnings	-US$59.00k

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0074
Gross Margin	57.86%
Net Profit Margin	-0.63%
Debt/Equity Ratio	630.7%

How did ISCO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/24 04:43
End of Day Share Price	2025/12/24 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

International Stem Cell Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Brookline Capital Markets
Maxim Jacobs	Edison Investment Research

International Stem Cell CorporationOTCPK:ISCO Stock Report